Clinical trial · no report yet · Phase 2
MiST
Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma
- NCT03654833 ↗
- Completed
- University of Leicester
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 4 | |
| Podcasts | 1 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Mesothelioma Stratified Therapy (MiST): A Stratified Multi-arm Phase IIa Clinical Trial to Enable Accelerated Evaluation of Targeted Therapies for Relapsed Malignant Mesothelioma
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Mesothelioma, Malignant
- Interventions
- Rucaparib; Abemaciclib; pembrolizumab & bemcentinib; Atezolizumab & Bevacizumab; Dostarlimab and Niraparib
- Arms
- MiST1 Rucaparib · Experimental
- MiST2 Abemaciclib · Experimental
- MiST3 Pembrolizumab & Bemcentinib · Experimental
- MiST4 Atezolizumab & Bevacizumab · Experimental
- MiST 5 Dostarlimab and Niraparib · Experimental
- Enrollment
- 186
- Primary outcomes
- Disease Control Rate (DCR) at 12 Weeks Assessed by Modified RECIST 1.1, in Patients With Relapsed Mesothelioma.
- Sponsor
- University of Leicester with British Lung Foundation, Clovis Oncology, Inc., Eli Lilly and Company, Merck Sharp & Dohme LLC, BerGenBio ASA, Roche Pharma AG, University Hospitals, Leicester, The Christie NHS Foundation Trust, GlaxoSmithKline
- Start
- Jan 28, 2019
- Primary completion
- Feb 21, 2023
- Results posted
- Yes
- Registry record
- NCT03654833 · updated Aug 17, 2026
Publications
linked from the registry- Fennell DA, King A, Mohammed S, Greystoke A, Anthony S, Poile C, Nusrat N, Scotland M, Bhundia V, Branson A, Brookes C, Darlison L, Dawson AG, Gaba A, Hutka M, Morgan B, Bajaj A, Richards C, Wells-Jordan P, Thomas A; MiST2 study group. Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial. Lancet Oncol. 2022 Mar;23(3):374-381. doi: 10.1016/S1470-2045(22)00062-6. Epub 2022 Feb 11. PubMed 35157829
- Fennell DA, King A, Mohammed S, Branson A, Brookes C, Darlison L, Dawson AG, Gaba A, Hutka M, Morgan B, Nicholson A, Richards C, Wells-Jordan P, Murphy GJ, Thomas A; MiST1 study group. Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial. Lancet Respir Med. 2021 Jun;9(6):593-600. doi: 10.1016/S2213-2600(20)30390-8. Epub 2021 Jan 27. PubMed 33515503